Coronavirus Disease Vaccines (COVID-19 Vaccines)
The sprint to advance a COVID-19 vaccine is hotly contested. More than 100 vaccines are in preclinical testing, according to 23 companies have moved their candidates into clinical trials. Broadly, some eight different vaccine technologies are in clinical trials: mRNA, DNA plasmid, protein subunit, adenovirus-vectored, measles-vectored, vesicular stomatitis virus-vectored, adenovirus associated-vectored and inactivated virus vaccines. Seven companies have planned or ongoing Phase II/III studies: AstraZeneca, Inovio, Moderna, Novavax, Pfizer/BioNtech, Sinopharm and Sinovac
Key Highlights
- Sixteen catalysts highlighted
- Eight vaccine technologies in clinical trials discussed
- Seven companies with planned or ongoing Phase II/III studies plus others in earlier-stage development analyzed
- Five investigative articles on trial design requirements and launch considerations with an early EUA
- Five to 12 experts cited per article
Scope
- Snapshot of upcoming high-impact, catalytic events for COVID-19 vaccines
- Insights investigative journalism related to COVID-19 vaccine development
- Exclusive analysis of various vaccine technologies prospects
- Considerations for trial protocols and approvals
Reasons to Buy
- Stay ahead of pipeline developments for COVID-19 vaccines
- Obtain a snapshot of future, key clinical trial events
- Access qualitative asset analysis based on talking to 5-12 KOLs about various vaccines in clinical trials
- Leverage investigative journalism content on prospects for vaccine approvals and market uptake
Introduction
Upcoming Vaccine Catalysts
Insights Investigative News on Vaccine Technologies
Insights Investigative News on Trial Protocols & Approvals
Appendix
List Of Tables
Upcoming Vaccine Catalysts
Summary of Insights Investigative News on Vaccine Technologies
Summary of Insights Investigative News on Trial Protocols & Approvals
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is
USD 1495 View ReportCoronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the
USD 2495 View ReportCoronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update
Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is
USD 1495 View ReportCoronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the
USD 2495 View ReportFill The Form For Sample Request